Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism TNIK inhibitors(TRAF2 and NCK-interacting protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization Biolexis TherapeuticsStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Preclinical | US | Biolexis TherapeuticsStartup | 21 Jul 2024 |
Obesity | Preclinical | US | Biolexis TherapeuticsStartup | 21 Jul 2024 |